SmithKline's Infanrix DTaP vaccine to be launched in February following FDA approval Jan. 29.
Executive Summary
SMITHKLINE INFANRIX ACELLULAR DTP VACCINE TO BE LAUNCHED IN FEBRUARY, following FDA approval Jan. 29. Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) will be the third DTaP vaccine on the market, following Wyeth-Lederle's Acel-Imune and Connaught's Tripedia. SB is bidding for a contract with the Vaccines for Children Program. New York-based GTFH will be handling advertising of Infanrix.